The ongoing trial is assessing the drug's performance both as a standalone therapy and in combination with Keytruda.

Programmed cell death-1, or PD-1, has become a headline-grabbing molecule best known for its role in cancer immunotherapies ...

how a protein capable of preventing programmed cell death can also promote it. Their study, led by Robert Horvitz, the David ...

Researchers from the National Defense Medical Center in Taiwan have identified an increased risk of psoriasis in patients ...

Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company.

The mechanisms underlying skin renewal are still poorly understood. Interleukin-38 (IL-38), a protein involved in regulating ...

The following is a summary of "Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and ...

Keytruda is a biologic that belongs to the programmed cell death protein 1 (PD-1) inhibitor drug class. Read on to learn about potential common, mild, and serious side effects of Keytruda.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held ...

Minghui Pharmaceutical has reported promising initial outcomes from its Phase I trial of MHB039A to treat patients with ...